Tamm I, Kornblau SM , Segall H, Kitada S, Scudiero DA, Tudor G, Y-H Q, Monks A, Sausville E, Andreeff M, Reed JC
Dunn, [email protected] This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This creates a fundamental design trade-off: optimizing for superior tissue penetration often comes at the cost of plasma persistence, and vice versa
[DOI] [PubMed] [Google Scholar] Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, et al
The pharmacokinetic profile difference is what matters clinically